What is your approach for adjuvant therapy when a patient has discordant Oncotype RS (e.g. <20) and MammaPrint (e.g. high risk Luminal B) in node negative HR+Her2- breast cancer?

In terms of the Mammprint, the question here is whether the patient is at low clinical risk or high clinical risk. A stage 1 patient is likely to be considered low clinical risk. In these patients, the MINDACT trial showed that Mammaprint was not able to accurately predict the benefit of chemotherap...

I have started using Mammaprint in low clinical risk patients to identify patients that might be able to safely stop endocrine therapy early (the ultra-low risk patients).
However, I then wonder if it makes sense to also check an Oncotype in case Mammaprint comes back as high risk to find out if the...